Stifel Canada Has Negative View of TSE:GUD FY2025 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Analysts at Stifel Canada lowered their FY2025 EPS estimates for shares of Knight Therapeutics in a research note issued on Monday, November 10th. Stifel Canada analyst J. Keywood now expects that the company will earn ($0.14) per share for the year, down from their prior estimate of ($0.10). The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q4 2025 earnings at $0.00 EPS and FY2026 earnings at $0.22 EPS.

Knight Therapeutics Price Performance

Shares of GUD stock opened at C$6.24 on Thursday. Knight Therapeutics has a 1 year low of C$5.09 and a 1 year high of C$6.55. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The firm’s 50 day moving average is C$6.01 and its 200-day moving average is C$6.04. The firm has a market capitalization of C$619.56 million, a price-to-earnings ratio of -156.00, a PEG ratio of -1,013.50 and a beta of 0.01.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, November 6th. The company reported C($0.04) earnings per share (EPS) for the quarter. Knight Therapeutics had a negative return on equity of 4.04% and a negative net margin of 8.81%.The firm had revenue of C$121.55 million for the quarter.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets.